In 2018, Varian Medical Systems announced it had signed an agreement to acquire all the outstanding shares of Sirtex Medical Limited (ASX: $SRX) ("Sirtex"), an Australia-based global life sciences company focused on interventional oncology therapies. Sirtex was acquired by the company for a huge USD 1.23 billion. The CEO of Sirtex was Nigel Linge and now he is leading another new innovative company Called OncoSil Medical Limited (ASX: $OSL). Now why are we telling you all about this? Our job as an investor is to connect the dots, so we can map the potential of the company. Now think why a CEO who sold his company for a billion dollars would join the company, it's obvious that he would have seen something in the company. But the question is can OncoSil really be the next Sirtex? We'll talk about the developments happening in the company, but if you don’t know about OncoSil here’s a little description of it.